What off‑label uses of metformin (generic name) are supported by clinical evidence?

Evidence-Supported Off-Label Uses of Metformin

Metformin has three well-established off-label uses supported by guideline-level evidence: polycystic ovary syndrome (PCOS), prevention of type 2 diabetes in prediabetes, and adjunctive weight management in obesity with metabolic comorbidities. 1, 2, 3

Primary Off-Label Indications with Strong Evidence

Polycystic Ovary Syndrome (PCOS)

• Metformin is recommended as second-line therapy for women with PCOS who cannot use combined oral contraceptives or who have type 2 diabetes or impaired glucose tolerance after lifestyle measures have failed. 1

• The drug improves menstrual cyclicity and ovulation rates in PCOS, though it is less effective than combined hormonal contraceptives for cycle regulation. 1

• For PCOS-related infertility, metformin is reserved for specific adjunctive roles: (1) obese patients (BMI ≥30) with documented insulin resistance or impaired glucose tolerance, (2) prevention of ovarian hyperstimulation syndrome in IVF cycles using long GnRH-agonist protocols, or (3) management of coexisting type 2 diabetes. 2

• Metformin does not increase live-birth rates when added to letrozole (the first-line ovulation-inducing agent), so routine combination therapy is not advised. 2

• Typical dosing starts at 850 mg once daily with breakfast, titrating to 1,700 mg daily in divided doses after 2–3 weeks, or alternatively begin with 500 mg with dinner and increase to 500 mg three times daily or 1,000 mg twice daily as tolerated. 1

• Common adverse effects are gastrointestinal (bloating, nausea, vomiting, diarrhea), especially during initiation. 1

• The FDA label notes that metformin therapy may result in ovulation in some anovulatory premenopausal women, requiring discussion of potential for unintended pregnancy. 4

Prediabetes and Type 2 Diabetes Prevention

• In the Diabetes Prevention Program, participants with impaired glucose tolerance who took metformin 850 mg twice daily lost 2.1 kg compared with 0.1 kg in the placebo group. 5

• Lifestyle therapy reduces progression to type 2 diabetes by approximately 58% in women with impaired glucose tolerance, establishing the benchmark against which metformin is compared. 1

• Metformin is appropriate for overweight PCOS patients to improve insulin sensitivity even without overt glucose intolerance, and may further aid menstrual regularity when combined hormonal contraceptives are not used. 3

Weight Management in Obesity with Metabolic Comorbidities

• The Endocrine Society guideline acknowledges that metformin promotes mild weight loss through multiple mechanisms, including AMP-activated protein kinase-mediated metabolic shifts away from lipid accretion. 5

• Metformin is not indicated as first-line therapy for obesity or cutaneous manifestations of PCOS; weight loss should be pursued through lifestyle modification before initiating pharmacologic agents. 1, 3

• For patients with diabetes who require weight loss, metformin and other weight-neutral or weight-reducing diabetes agents should be tried before adding medications designed specifically for weight loss. 5

Emerging Off-Label Uses with Preliminary Evidence

Prevention of Antipsychotic-Induced Weight Gain

• Metformin is the only pharmacological agent that has demonstrated efficacy for preventing antipsychotic-induced weight gain, reducing weight gain by 4.03 kg (95% CI -5.78 to -2.28 kg) when co-commenced with antipsychotic medicines. 6

• A 2024 guideline using AGREE II framework and GRADE methods provides strong recommendations for co-commencement of metformin at initiation with an antipsychotic or commencement if certain criteria are present. 6

Gestational Diabetes and Antenatal Steroid Management

• A 2026 randomized trial demonstrated that metformin (425 mg three times daily before meals and 850-1700 mg at 10 pm) was safe and effective in preventing betamethasone-induced maternal hyperglycemia and neonatal hypoglycemia in pregnant women receiving antenatal corticosteroids. 7

• Mean maternal total and postprandial glucose values were significantly lower in the metformin group (121 vs 127 mg/dL, P=0.01; and 129 vs 138 mg/dL, P=0.009), and neonatal hypoglycemia rate was lower (21% vs 40%, P=0.04). 7

• The FDA label states that published post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when used during pregnancy, though studies have methodological limitations. 4

• Limited published studies report that metformin is present in human milk at infant doses approximately 0.11% to 1% of the maternal weight-adjusted dosage. 4

Acne Vulgaris

• A 2023 systematic review found some evidence for the use of metformin particularly in acne, with the pathophysiology of acne vulgaris well suited to the pharmacological profile of metformin. 8

• The evidence base is of mixed quality, but there is scope for clinicians to consider metformin as an adjunct therapy in acne, especially when associated with PCOS. 8

Off-Label Uses with Insufficient or Negative Evidence

Peripheral Artery Disease

• A 2026 randomized trial (PERMET) demonstrated that metformin did not improve 6-minute walk distance at 6-month follow-up compared with placebo in people with PAD without diabetes (adjusted between-group difference: 1.1 m, 95% CI -16.3 to 18.6 m, P=0.90). 9

• Metformin did not significantly improve any secondary outcomes including maximal treadmill walking time, pain-free treadmill walking time, or Walking Impairment Questionnaire scores. 9

• These results do not support metformin for improving walking performance in patients with PAD. 9

Non-Alcoholic Fatty Liver Disease (NAFLD)

• Metformin commonly is used as an off-label drug in NAFLD, but it worsens inflammation and should not be used for this purpose according to the latest research. 10

• Conversely, metformin decreased the risk of death in patients with liver cirrhosis and is an effective agent in the prevention and improvement of survival in patients with hepatocellular carcinoma. 10

Important Safety Considerations

• Metformin is contraindicated in severe renal impairment (eGFR below 30 mL/min/1.73 m²) due to risk of lactic acidosis. 4

• Metformin is not recommended in patients with hepatic impairment, as use has been associated with some cases of lactic acidosis. 4

• Metformin should be discontinued before contrast-enhanced imaging in patients with reduced renal function. 1

• In elderly patients, dose selection should be cautious, usually starting at the low end of the dosing range, with more frequent renal function assessment. 4

Clinical Pitfalls to Avoid

• Do not use metformin as first-line therapy for PCOS-related menstrual irregularities; combined oral contraceptives are superior for cycle regulation and endometrial protection. 1, 3

• Do not routinely combine metformin with letrozole for PCOS-related infertility, as it does not improve live-birth rates. 2

• Do not prescribe metformin for NAFLD based on older literature; current evidence suggests it may worsen inflammation. 10

• Do not continue metformin beyond a positive pregnancy test when used solely for infertility management, unless treating gestational diabetes or other metabolic indications. 2